SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis
11 references·4 citing·43 second hop
Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis (2006)Pricing and reimbursement of in-patent dr…The Patents-Based Pharmaceutical Development Process (2005)The Patents-Based Pharmaceuti…Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures (2005)Ten years of marketing approv…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…Health care reform in Belgium (2005)Health care reform in BelgiumThe impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)The impact of price regulatio…Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Examining the link between price regulation and pharmaceutical R&D investment (2004)Examining the link between pr…Developing Guidance for Budget Impact Analysis (2001)Developing Guidance for Budge…The influence of economic evaluation studies on decision making. (2000)The influence of economic eva…The German experience in reference pricing (1998)The German experience in refe…Methods for the economic evaluation of health care programmes (1987)Methods for the economic eval…Price control as a strategy for pharmaceutical cost containment—What has been achieved in Norway in the period 1994–2004? (2008)Price control as a strategy f…Insight into recent reforms and initiatives in Austria: implications for key stakeholders (2008)Insight into recent reforms a…Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries (2007)Prices and distribution margi…Pharmaceutical policy in Italy: towards a structural change? (2004)Pharmaceutical policy in Ital…Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Theory versuspractice: a review of ?willingness-to-pay? in health and health care (2001)Measuring Preferences for Cost-Utility Analysis (2007)Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed? (2018)A DECADE OF EXPERIENCE (2000)Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process (2002)Selection of new health technologies for assessment aimed at informing decision making: A survey among horizon scanning systems (2006)How can we regulate medicines better? (2007)Recent National and Regional Drug Reforms in Sweden (2008)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)Cost effectiveness analysis in health care: contraindications (2002)Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet (2009)Multicriteria Decision Analysis for Including Health Interventions in the Universal Health Coverage Benefit Package in Thailand (2012)Patent Buy-Outs: A Mechanism for Encouraging Innovation (1997)Is Technological Change In Medicine Worth It? (2001)The price of innovation: new estimates of drug development costs (2003)Forecasting drug utilization and expenditure in a metropolitan health region (2010)Orphan Drugs for Rare Diseases (2012)Drug repurposing for cancer therapy, easier said than done (2019)Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature (1992)Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. (2003)Direct Cost Analysis of Intensive Care Unit Stay in Four European Countries: Applying a Standardized Costing Methodology (2012)UPDATE OF THE DUTCH MANUAL FOR COSTING IN ECONOMIC EVALUATIONS (2012)Specification Tests in Econometrics (1978)Firm Resources and Sustained Competitive Advantage (1991)Firm resources and sustained competitive advantage (2004)Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry? (2007)Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation (2013)The impact of regulation on innovation (2016)An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments (1973)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Pharmaceutical Price Controls and Entry Strategies (2007)Market size and pharmaceutical innovation (2015)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Measurement of health state utilities for economic appraisal (1986)The Estimation of a Preference-Based Measure of Health From the SF-12 (2004)Comparative approaches to pharmaceutical price regulation in the European Union. (2002)Reference-Based Pricing Schemes (2002)Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 1987Methods for the economic evaluation of health care programmes4,274 cited
  • 2004The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s344 cited
  • 2001Developing Guidance for Budget Impact Analysis227 cited
  • 2000The influence of economic evaluation studies on decision making.201 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited
  • 2004Examining the link between price regulation and pharmaceutical R&D investment145 cited
  • 2005Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures109 cited
  • 2005The Patents-Based Pharmaceutical Development Process98 cited
  • 1998The German experience in reference pricing84 cited
  • 2005Health care reform in Belgium49 cited

Cited by

  • 2008Price control as a strategy for pharmaceutical cost containment—What has been achieved in Norway in the period 1994–2004?71 cited
  • 2008Insight into recent reforms and initiatives in Austria: implications for key stakeholders70 cited
  • 2004Pharmaceutical policy in Italy: towards a structural change?

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

60 cited
  • 2007Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries56 cited